Search for: "Sanofi"
Results 41 - 60
of 1,195
Sort by Relevance
|
Sort by Date
20 Dec 2023, 5:00 am
Sanofi will affect innovation and the pharmaceutical industry. [read post]
15 Dec 2023, 1:16 pm
The post Sanofi Abandons Deal For Rare Disease Drug Amid FTC’s Monopoly Concerns appeared first on Above the Law. [read post]
15 Dec 2023, 12:48 pm
This week in Other Barks & Bites: a group of authors filed a trimmed-down lawsuit against Meta accusing the company of infringing copyright to train generative AI models; the FTC authorizes a lawsuit against Sanofi accusing a potential acquisition of being a move to monopolize Pompe disease drug development; and Chinese courts publish rulings to combat malicious trademarks. [read post]
15 Dec 2023, 12:48 pm
This week in Other Barks & Bites: a group of authors filed a trimmed-down lawsuit against Meta accusing the company of infringing copyright to train generative AI models; the FTC authorizes a lawsuit against Sanofi accusing a potential acquisition of being a move to monopolize Pompe disease drug development; and Chinese courts publish rulings to combat malicious trademarks. [read post]
14 Dec 2023, 10:00 pm
August: In Nigeria, the French multinational pharmaceutical and healthcare company Sanofi S.A., filed a petition with the Corporate Affairs Commission (CAC) in 2019, alleging that the registration of Sanofi Integrated Services Limited, Sanofi Nigeria Enterprises Limited, and Sanofi Nigerian Enterprise was unlawful. [read post]
14 Dec 2023, 12:15 pm
Sanofi decisions, respectively. [read post]
14 Dec 2023, 12:15 pm
Sanofi decisions, respectively. [read post]
13 Dec 2023, 1:29 am
The appeal case T 1356/21 related to the novelty of Sanofi's patent (EP2571517). [read post]
8 Dec 2023, 7:58 am
Sanofi is an important case, but it won’t transform patent law on its own. [read post]
7 Dec 2023, 11:17 am
This appointment positions Buchanan at the forefront of a critical legal battle against insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi – who control nearly the entire U.S. insulin market – as well as the nation’s three largest pharmacy benefit managers (PBMs), CVS Caremark, Express Scripts, and OptumRx, over allegations these companies used unlawful, unfair, and deceptive practices to aggressively hike the cost of insulin and other diabetes medications. [read post]
7 Dec 2023, 6:00 am
., and Sanofi-Aventis U.S. [read post]
4 Dec 2023, 10:00 pm
Sanofi , 143 S. [read post]
3 Dec 2023, 9:15 am
Sanofi 598 U.S. 594 (2023) will be one of the most significant, if not the most significant Supreme Court patent decision of 2023. [read post]
3 Dec 2023, 9:15 am
Sanofi 598 U.S. 594 (2023) will be one of the most significant, if not the most significant Supreme Court patent decision of 2023. [read post]
29 Nov 2023, 8:41 am
by Dennis Crouch The Supreme Court is set to consider several significant patent law petitions addressing a range of issues from the application of obviousness standards, challenges to PTAB procedures, interpretation of joinder time limits IPR, to the proper scope patent eligibility doctrine. [read post]
24 Nov 2023, 6:08 pm
From Matthew Wiener: On November 29, 2023, the Supreme Court will hear argument in Securities and Exchange Commission v. [read post]
22 Nov 2023, 3:41 am
Sanofi, the 2023 Supreme Court invalidated Amgen’s broad functional genus claim covering for monoclonal antibodies that bind to PCSK9 to lower cholesterol. [read post]
17 Nov 2023, 6:00 am
The Amgen and Sanofi dispute is another case where proceedings are pending in multiple UPC fora, this time before the Central Division (Pari [read post]
14 Nov 2023, 9:10 am
Seeger Weiss attorneys Chris Seeger, David Buchanan and Steven Daroci filed a lawsuit on behalf of Arlington County, Virginia against insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, and pharmacy benefit managers (PBMs) CVS Caremark, Express Scripts and OptumRx, for their alleged role in a scheme to aggressively inflate the price of insulin and other diabetes medications. [read post]
26 Oct 2023, 1:21 am
Toujours dans le cadre de l'action en contrefaçon engagée par Amgen contre Sanofi devant la division locale de Munich, la présente ordonnance concerne le calcul des délais pour soulever une objection préliminaire (R.19.1 RoP) et déposer le mémoire en défense (R.23 RoP), respectivement de 1 et 3 mois à compter de la signification du mémoire en demande. [read post]
